Answers are grounded in this paper and cite their sources.
Technical description of MCSC-Film reactor reveals enhanced hydrogen production in gas-fired power plants, indicating significant carbon reduction potential.
Technical description of the MCSC-Film reactor ("Tin Cascade") — a bolt-on module for decarbonizing existing gas-fired power plants. Unlike conventional bubble-column methane pyrolysis, MCSC-Film employs a falling film of molten tin over inclined graphite plates inside a horizontal reactor tube. Natural gas flows upward through the film, decomposing into hydrogen (H2) and solid carbon (C) within 0.5–1.5 seconds at 950–1050 °C. Carbon is continuously washed down by the tin flow into a vertical separator, where it floats to the surface and is mechanically removed. Clean tin is recirculated by a magnetic-drive pump. Key design features:- Horizontal tube reactor (8 m length, 1.4 m outer diameter)- Only 3 tonnes of molten tin (vs. 150 tonnes in conventional designs)- Graphite plates with micro-grooves for film stabilization (10–12 plates, 15–20° inclination)- Induction heating via 4-zone copper coils (6–8 MW total)- Corundum castable lining (100 mm, seamless) over ceramic fiber insulation (150 mm)- Inconel 617 pressure shell (5 MPa, 20 mm wall)- Hydrogen curtain at reactor outlet to prevent soot deposition- Carbon separation via density-driven flotation in a vertical separator- Tungsten scraper for continuous carbon removal- Double-gate lock hopper with nitrogen purge for carbon discharge- Bolt-on integration with existing CCGT power plants- Emergency bypass: 2-second switchover to direct natural gas feed Performance (MCSC-Film 300):- Thermal capacity: 300 MW- Hydrogen output: 85,000 Nm³/h- Solid carbon output: 2.5 t/h (22,000 t/yr)- CAPEX: ~$32–35 million- Payback: <10 months (with EU ETS), ~2 years (carbon revenue only) Performance (MCSC-Film 50, transportable):- Thermal capacity: 50 MW- Hydrogen output: ~14,000 Nm³/h- Carbon output: ~0.4 t/h (3,500 t/yr)- CAPEX: ~$8–10 million- Payback: ~1.5 years This document is published as an open defensive disclosure under the ARI framework to establish prior art and prevent monopolization of the technology.
No takes yet. Share an insight, caveat, or question.
Vadim Kharlamov (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: